- Esperion is deeply undervalued company selling a new treatment in the huge and lucrative market for lowering LDL cholesterol.
- ESPR is highly leveraged to Covid-reopening, but unlike many industries, it has gotten no bump from vaccine news. ESPR is financially healthy and will survive and thrive.
- Analysts and the independent ICER have convincingly shown Nexletol can generate up to $3B per year in revenue. If so, ESPR would be fairly valued at more than $300.
- ESPR is a prime target to be acquired by a large pharmaceutical company.
- Despite ESPR's promise, it has one of the highest short interests in the entire market. Institutions own more than 122% of all shares that exist. No, that was not a typo! This may mean extreme danger for ESPR shorts and lower risk for those who buy.
For further details see:
Esperion Therapeutics: Deeply Undervalued With An Extremely High Short Interest